Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7568469 | 0.90 | NOTUM (0.50) | NOTUMHSD11B1ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL1747817 | 0.89 | NOTUM (0.49) | NOTUMHSD11B1ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL29791451 | 0.85 | NOTUM (0.44) | NOTUMHSD11B1MAPT | |
| SCHEMBL14062149 | 0.85 | NOTUM (0.44) | NOTUMHSD11B1MAPT | |
| SCHEMBL12934775 | 0.85 | OPRM1 (0.46) | NOTUMHSD11B1OPRM1OPRL1KCNH2 | |
| SCHEMBL12935088 | 0.84 | SLC18A3 (0.46) | NOTUMHSD11B1ALDH1A1MAPK1OPRM1 | |
| SCHEMBL14639364 | 0.84 | NOTUM (0.43) | NOTUMHSD11B1OPRM1OPRL1MAPT | |
| SCHEMBL1747722 | 0.83 | NOTUM (0.43) | NOTUMHSD11B1ALDH1A1CYP2C19OPRM1 | |
| SCHEMBL1747820 | 0.82 | HDAC1 (0.49) | NOTUMHSD11B1MAPK1HDAC1HDAC6 | |
| SCHEMBL12934990 | 0.82 | OPRM1 (0.43) | NOTUMHSD11B1OPRM1OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | NOTUM 366/4885HSD11B1 2836/4885ALDH1A1 1361/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | NOTUM 366/4885HSD11B1 2836/4885ALDH1A1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.